Biotoxtech Co., Ltd.
Financials
Valuation Metrics
Biotoxtech Co., Ltd.'s Market Cap is ₩368B. At end of 2025 it was ₩449B. Ranked #1957 of 2,421 in KR market (top 81%), #1231 of 1,640 on KOSDAQ (top 75%), #208 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 90%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 36.78B KRW | KR#1,957/2,421 Sec#208/231 |
| Revenue | 52.48B KRW | KR#1,757/2,421 Sec#119/231 |
| Net Income | -7.12B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 132.35B KRW | KR#1,590/2,421 Sec#124/231 |
| Net Assets | 22.38B KRW | KR#2,262/2,421 Sec#212/231 |
| Employees | 230 | KR#992/2,421 Sec#83/231 |
| Value | ||
| P/B | 1.64x | KR#1,824/2,421 Sec#130/231 |
| P/S | 0.70x | KR#1,144/2,421 Sec#58/231 |
| FCF Yield | 12.28% | KR#528/2,421 Sec#17/231 |
| Profitability | ||
| ROE | -31.81% | KR#2,198/2,421 Sec#180/231 |
| ROA | -5.38% | KR#1,949/2,421 Sec#141/231 |
| Op. Margin | -6.60% | KR#1,913/2,421 Sec#126/231 |
| Revenue Growth | 20.88% | KR#532/2,421 Sec#49/231 |
| Financial Health | ||
| Debt Ratio | 491.29% | KR#2,325/2,421 Sec#226/231 |
| Total Debt | 41.50B KRW | KR#1,076/2,421 Sec#74/231 |
| FCF | 4.52B KRW | KR#927/2,421 Sec#64/231 |
| Cash | 14.85B KRW | KR#1,436/2,421 Sec#114/231 |
| Current Ratio | 0.54x | KR#2,117/2,421 Sec#203/231 |
| Performance | ||
| 1Y Return | -29.08% | KR#1,530/2,421 Sec#123/231 |
| 1M Return | 4.30% | KR#806/2,421 Sec#58/231 |
| From 52W High | -43.99% | KR#1,104/2,421 Sec#82/231 |
| 1Y MDD | -49.48% | KR#960/2,421 Sec#76/231 |
| Trading | ||
| Volume | 1,454 shares | KR#2,298/2,421 Sec#220/231 |
| Trading Value | 3.3M KRW | KR#2,350/2,421 Sec#224/231 |
| Foreign Own. | 2.15% | KR#1,576/2,421 Sec#151/231 |
| Per Share | ||
| EPS | -446 KRW | KR—/2,421 Sec—/231 |
| BPS | 1,403 KRW | KR#2,216/2,421 Sec#193/231 |
Company Info
The company, a non-clinical CRO specialist listed on KOSDAQ in 2007, owns the subsidiary KiforPrime Research. It performs toxicity, safety, and efficacy evaluations for medicines, cell therapies, gene therapies, and chemicals, providing professional contract research services through GLP certification. In line with global industry trends, the company is expanding primate non-clinical trials and pursuing innovation by establishing experimental animal facilities and offering consulting services. Biotoxtech was established in 2000 and is headquartered in Chungcheongbuk-do, Cheongju-si.